Karuna Therapeutics Stock Fundamentals
By evaluating key metrics such as revenue growth, profitability, cash flow trends, and balance sheet strength, investors can better assess Karuna Therapeutics' long-term financial health and intrinsic value.
Karuna |
Karuna Therapeutics Company Return On Asset Analysis
Karuna Therapeutics' Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Current Karuna Therapeutics Return On Asset | -0.25 |
Most of Karuna Therapeutics' fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Karuna Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
CompetitionBased on the latest financial disclosure, Karuna Therapeutics has a Return On Asset of -0.2471. This is 97.18% lower than that of the Biotechnology sector and 98.95% lower than that of the Health Care industry. The return on asset for all United States stocks is 76.5% higher than that of the company.
Karuna Therapeutics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Karuna Therapeutics's current stock value. Our valuation model uses many indicators to compare Karuna Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Karuna Therapeutics competition to find correlations between indicators driving Karuna Therapeutics's intrinsic value. More Info.Karuna Therapeutics is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Karuna Therapeutics' earnings, one of the primary drivers of an investment's value.Karuna Return On Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Karuna Therapeutics' direct or indirect competition against its Return On Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Karuna Therapeutics could also be used in its relative valuation, which is a method of valuing Karuna Therapeutics by comparing valuation metrics of similar companies.Karuna Therapeutics is currently under evaluation in return on asset category among its peers.
Karuna Fundamentals
| Return On Equity | -0.36 | |||
| Return On Asset | -0.25 | |||
| Operating Margin | (755.64) % | |||
| Current Valuation | 11.35 B | |||
| Shares Outstanding | 38.2 M | |||
| Shares Owned By Insiders | 4.98 % | |||
| Shares Owned By Institutions | 86.32 % | |||
| Number Of Shares Shorted | 1.97 M | |||
| Price To Earning | (19.88) X | |||
| Price To Book | 10.05 X | |||
| Price To Sales | 19,265 X | |||
| Revenue | 654 K | |||
| Gross Profit | 10.64 M | |||
| EBITDA | (493.08 M) | |||
| Net Income | (433.68 M) | |||
| Cash And Equivalents | 407.41 M | |||
| Cash Per Share | 13.60 X | |||
| Total Debt | 16.69 M | |||
| Debt To Equity | 0.01 % | |||
| Current Ratio | 17.77 X | |||
| Book Value Per Share | 32.94 X | |||
| Cash Flow From Operations | (385.82 M) | |||
| Short Ratio | 3.60 X | |||
| Earnings Per Share | (11.74) X | |||
| Price To Earnings To Growth | 1.46 X | |||
| Target Price | 324.17 | |||
| Number Of Employees | 339 | |||
| Beta | 1.15 | |||
| Market Capitalization | 12.6 B | |||
| Total Asset | 1.34 B | |||
| Retained Earnings | (997.89 M) | |||
| Working Capital | 1.25 B | |||
| Current Asset | 6.24 M | |||
| Current Liabilities | 8.73 M | |||
| Net Asset | 1.34 B |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Other Consideration for investing in Karuna Stock
If you are still planning to invest in Karuna Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Karuna Therapeutics' history and understand the potential risks before investing.
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon |